Online inquiry

IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12921MR)

This product GTTS-WQ12921MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FZD10 gene. The antibody can be applied in Synovial sarcoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_007197.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 11211
UniProt ID Q9ULW2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12921MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1910MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGN 150998
GTTS-WQ2253MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ5945MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CL-2C
GTTS-WQ8644MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ11877MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ11239MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI3902
GTTS-WQ1257MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-165
GTTS-WQ15786MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XmAb-13676
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW